WO2022017468A1 - Pd-l1/lag-3双特异性抗体制剂及其制备方法和用途 - Google Patents
Pd-l1/lag-3双特异性抗体制剂及其制备方法和用途 Download PDFInfo
- Publication number
- WO2022017468A1 WO2022017468A1 PCT/CN2021/107878 CN2021107878W WO2022017468A1 WO 2022017468 A1 WO2022017468 A1 WO 2022017468A1 CN 2021107878 W CN2021107878 W CN 2021107878W WO 2022017468 A1 WO2022017468 A1 WO 2022017468A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- formulation
- lag
- arginine
- liquid
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Definitions
- the present invention relates to the field of antibody formulations. More specifically, the present invention relates to pharmaceutical formulations comprising bispecific antibodies that bind both PD-L1 and LAG-3, in particular stable liquid formulations, lyophilized formulations and reconstituted stable liquid formulations, and for use in the preparation of such formulations. Methods of said pharmaceutical formulations, and therapeutic and/or prophylactic uses of said pharmaceutical formulations.
- Drug stability is one of the important indicators to ensure the effectiveness and safety of drugs. Obtaining a good formulation is a key condition to ensure that the drug product maintains its efficacy and safety during the shelf life.
- Due to the complexity of the antibodies themselves and their degradation pathways it is currently impossible to predict the formulation conditions required to optimize antibody stability. Especially considering that different antibodies often have very different CDR sequences, antibody structures, and these sequence and structure differences can lead to different stability properties of different antibodies in solution. Therefore, based on the strict requirements on the safety and efficacy of human antibodies, it is necessary to optimize the optimal formulation for each antibody individually.
- LAG-3 is mainly expressed on the cell membrane surface of activated T cells and NK cells, and plays a role in inhibiting the activity of immune cells to kill tumor cells.
- the PD-1/PD-L1 signaling pathway is one of the main mechanisms by which the immune system suppresses tumor clearance, which has been widely proven in clinical practice. Simultaneous targeting of the LAG-3/MHC II signaling pathway and the PD-1/PD-L1 signaling pathway has also been shown to have a certain synergistic effect in clinical applications. Therefore, designing a bispecific antibody that can block PD-1/PD-L1 signaling pathway and LAG-3/MHC II at the same time has great clinical application value.
- the present invention addresses the above needs by providing pharmaceutical formulations containing bispecific antibodies that specifically bind to PD-L1 and LAG-3.
- the antibody preparation of the present invention exhibits excellent stability against various stability influencing factors.
- the present invention provides a liquid antibody formulation comprising (i) a PD-L1/LAG-3 bispecific antibody, (ii) a buffer, (iii) a stabilizer, and (iv) Surfactant.
- the liquid antibody formulation further comprises (v) a chelating agent.
- the bispecific antibody structure of PD-L1/LAG-3 of the present invention is shown in Figure 1, wherein antigen A is LAG-3, antigen B is PD-L1, and its structure comprises:
- VH represents heavy chain variable region
- CH represents heavy chain constant region
- Fc comprises CH2, CH3, and optionally CH4;
- CH1, CH2, CH3 and CH4 represent domains 1, 2, 3 and 4 of the heavy chain constant region, respectively;
- X may be absent, or, when present, represent a linker
- VHH represents a single domain antigen binding site
- VL represents light chain variable region
- CL represents the light chain constant region
- the PD-L1/LAG-3 bispecific antibody of the present invention comprises the sequences shown in the following table:
- Anti-LAG-3 antibody HCDR3 (HCDR3 of an exemplary VH of formula (I)) SEQ ID NO: 15 Anti-LAG-3 antibody LCDR1 (LCDR1 of exemplary VL of formula (II)) SEQ ID NO: 16 Anti-LAG-3 antibody LCDR2 (LCDR2 of VL of exemplary formula (II)) SEQ ID NO: 17 Anti-LAG-3 antibody LCDR3 (LCDR3 of exemplary VL of formula (II)) SEQ ID NO: 18 Anti-LAG-3 antibody heavy chain (exemplary VH-CH1-Fc of formula (I)) SEQ ID NO: 19
- the PD-L1/LAG-3 bispecific antibody is the bispecific antibody IGN-LP disclosed in PCT Application No. PCT/CN2020/073964 (International Application Date: January 23, 2020).
- the PD-L1/LAG-3 bispecific antibody is recombinantly expressed in HEK 293 cells or CHO cells.
- the concentration of PD-L1/LAG-3 diabody in the liquid antibody formulation of the present invention is about 10-200 mg/ml. In another embodiment, the concentration of PD-L1/LAG-3 diabody in the liquid antibody formulation of the present invention is about 20-100 mg/ml, eg, about 20, 25, 30, 35, 40, 45, 50 , 55, 60, 70, 80, 90 or 100 mg/ml, preferably the concentration of PD-L1/LAG-3 double antibody is about 20-60 mg/ml, more preferably about 20-30 mg/ml.
- the concentration of buffer in the liquid antibody formulation of the invention is about 5-50 mM. In one embodiment, the concentration of buffer in the liquid antibody formulation of the invention is about 5-30 mM, eg, about 5, 10, 15, 20, 25, 30 mM.
- the buffer is histidine buffer, citrate buffer, acetate buffer, phosphate buffer, preferably, the buffer is histidine buffer. In one embodiment, the buffer is a histidine buffer, preferably, the buffer consists of histidine and histidine hydrochloride. In a preferred embodiment, the buffer is about 5-30 mM histidine buffer, eg about 5-15 mM, such as about 10 mM histidine buffer. In another embodiment, the histidine buffer used in the formulations of the present invention consists of, for example, about 0.85 mg/ml histidine and about 0.97 mg/ml histidine hydrochloride.
- the stabilizer in the liquid antibody formulation of the present invention is selected from the group consisting of polyols (eg, sorbitol, mannitol, or combinations thereof), carbohydrates (eg, sucrose, trehalose, maltose, or combinations thereof) , amino acids (eg, arginine hydrochloride, methionine, glycine, proline, and combinations or salts thereof), and any combination thereof.
- the stabilizer comprises about 10-80 mg/ml sorbitol, such as 10, 20, 25, 30, 35, 40, 45, 50, 55, 60, 70, 80 mg/ml sorbitol, Preferably about 15-25 mg/ml.
- the stabilizer comprises about 20-100 mg/ml sucrose, such as 20, 30, 40, 50, 60, 70, 80, 90, 100 mg/ml sucrose, preferably about 40-80 mg/ml sucrose.
- the stabilizer comprises arginine, eg, about 50 mM-200 mM, eg, 60-180 mM, preferably about 70-170 mM.
- the arginine is arginine hydrochloride.
- the stabilizer has arginine as a single component, the arginine being about 120-200 mM, preferably about 150-180 mM, such as 150, 155, 160, 165, 170, 175, 180 mM , more preferably about 160-170 mM.
- the arginine is arginine hydrochloride.
- the stabilizer comprises a combination of sorbitol and arginine, the arginine being about 60-100 mM, preferably about 70-90 mM, such as 70, 75, 80, 85, 90 mM; the sorbitol
- the alcohol is about 10-30 mg/ml, preferably about 15-25 mg/ml, eg 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 mg/ml.
- the arginine is arginine hydrochloride.
- the stabilizer has sucrose as a single component, the sucrose being about 60-100 mg/ml, preferably about 70-90 mg/ml, eg, 70, 75, 80, 85, 90 mg/ml.
- the stabilizer comprises a combination of sucrose and arginine, the arginine being about 60-100 mM, preferably about 70-90 mM, such as 70, 75, 80, 85, 90 mM; the sucrose About 20-60 mg/ml, preferably about 35-45 mg/ml, eg 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45 mg/ml.
- the arginine is arginine hydrochloride.
- the surfactant is a nonionic surfactant.
- the surfactant is selected from the group consisting of polysorbate surfactants, poloxamers, polyethylene glycols.
- the surfactant is selected from the group of polysorbate surfactants.
- the surfactant in the liquid antibody formulation of the present invention is polysorbate-80.
- the concentration of surfactant in the liquid antibody formulation of the invention is about 0.1-1 mg/ml. In one embodiment, the concentration of surfactant in the liquid antibody formulation of the invention is about 0.2-0.8 mg/ml, eg, about 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8 mg/ml.
- the chelating compound in the liquid formulation of the present invention is a carboxylic acid type chelating agent.
- the chelating agent is selected from the group consisting of disodium edetate, aminotriacetic acid, diethylenetriaminepentaacetic acid, citric acid, tartaric acid, gluconic acid, hydroxyethylethylenediaminetriacetic acid, diethylenediamine Hydroxyethylglycine.
- the chelating agent is selected from disodium edetate.
- the concentration of the chelating agent in the liquid antibody formulation of the invention is about 0.005-0.05 mg/ml. In one embodiment, the concentration of the chelating agent in the liquid antibody formulation of the invention is about 0.008-0.018 mg/ml, eg, about 0.008, 0.009, 0.010, 0.012, 0.014, 0.018 mg/ml.
- the pH of the liquid formulation is about 5.5-6.5. In some embodiments, the pH of the liquid formulation is any of about 5.5-6.5, eg, about 5.6, 5.8, 6.0, 6.2, 6.4. Preferably, the pH of the formulation is 5.8-6.4, eg, pH is 6.0 ⁇ 0.2 or 6.2 ⁇ 0.2, preferably pH is 6.0.
- liquid antibody formulation of the present invention comprises:
- PD-L1/LAG-3 diabody protein e.g. 20, 25, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90 or 100 mg/ml, preferably 20-60 mg/ml, more preferably 20-30 mg/ml;
- arginine such as 150, 155, 160, 165, 170, 175, 180 mM, preferably about 160-170 mM; or a combination of sorbitol and arginine, said arginine being about 60 - 100 mM, eg 60, 65, 70, 75, 80, 85, 90, 100 mM, preferably about 70-90 mM
- the sorbitol is about 10-30 mg/ml, preferably about 15-25 mg/ml, eg 15, 16 , 17, 18, 19, 20, 21, 22, 23, 24, 25 mg/ml; or about 60-100 mg/ml of sucrose, preferably about 70-90 mg/ml, such as 70, 75, 80, 85, 90 mg /ml; or a combination of sucrose and arginine, the arginine being about 60-100 mM, such as 60, 65, 70, 75, 80, 85, 90, 100 mM, preferably about 70-90 mM
- the liquid antibody formulation further comprises (v) about 0.008-0.018 mg/ml, such as about 0.008, 0.009, 0.010, 0.012, 0.014, 0.018 mg/ml disodium edetate;
- the pH of the liquid formulation is about 5.5-6.5, preferably the pH is about 5.8-6.4, eg, the pH is 6.0 ⁇ 0.2 or 6.2 ⁇ 0.2, eg, about 6.0.
- the liquid antibody preparation comprises:
- sorbitol a combination of sorbitol and arginine, said arginine being about 60-100 mM and said sorbitol being about 10-30 mg/ml; or
- a combination of sucrose and arginine is about 60-100 mM, and the sucrose is about 20-60 mg/ml;
- pH of the liquid formulation is about 5.8-6.4;
- the liquid antibody preparation comprises:
- sorbitol a combination of sorbitol and arginine, said arginine being about 70-90 mM and said sorbitol being about 15-25 mg/ml; or
- a combination of sucrose and arginine is about 70-90 mM, and the sucrose is about 35-45 mg/ml;
- pH of the liquid formulation is about 5.8-6.4;
- the liquid antibody preparation comprises:
- the liquid formulations of the present invention are stable for long-term storage, eg, at least 24 months or more.
- the liquid formulation of the present invention may be at about -80°C to about 45°C, eg, -80°C, about -30°C, about -20°C, about 0°C, about 5°C, about 25°C, about Store at least 10 days, at least 20 days, at least 1 month, at least 2 months, at least 3 months, at least 4 months at 35°C, about 38°C, about 40°C, about 42°C, or about 45°C , at least 5 months, at least 6 months, at least 7 months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, at least 12 months, at least 18 months, at least 24 months , at least 36 months, or longer, and is stable.
- the liquid formulations of the present invention are storage stable for at least 24 months. In yet another embodiment, the liquid formulations of the present invention are stable at at least 40°C. In yet another embodiment, the liquid formulations of the present invention are stable at about 2°C-8°C for at least 3 months, preferably at least 12 months, more preferably at least 24 months. In one embodiment, the liquid formulations of the present invention are stable at room temperature or, for example, about 25°C for at least 2 months, preferably at least 3 months, more preferably at least 6 months. In yet another embodiment, the liquid formulations of the present invention are stable at about 40°C for at least 2 weeks, preferably at least 1 month.
- the stability of the formulation can be indicated by detecting changes in the formulation's appearance, visible foreign matter, protein content, turbidity, purity, surfactant content, relative binding activity, and/or charge variants. In one embodiment, it may be in a forced experiment under high temperature stress, eg after storage at 40°C ⁇ 2°C for at least 1 week, 2 weeks or preferably 1 month, or in an accelerated experiment, eg at 25°C ⁇ 2°C After storage for at least 1 month or 2 months, or in long-term experiments, such as after storage at 5°C ⁇ 3°C for at least 2 months or 3 months, or in shaking experiments (eg, at room temperature, protected from light, 650 r/min)
- the stability of the liquid formulation of the present invention was tested in freeze-thaw experiments (eg, repeated freeze-thaw cycles at -30°C/room temperature for 5 days).
- the stability of the liquid formulations of the invention is tested relative to an initial value, eg, an initial value on day 0
- the stability of the liquid formulations of the present invention is visually inspected for stability, wherein the liquid formulations of the present invention remain clear to slightly opalescent in appearance , is a colorless to slightly yellow liquid with no foreign matter. In one embodiment, no visible foreign matter is present in the formulation upon visual inspection under a clarity tester.
- the stability of the liquid formulations of the present invention is checked by measuring changes in protein content after storage, or after shaking experiments, or after freeze-thaw experiments, wherein, for example, by ultraviolet spectrophotometry (UV) methods, relative to From the initial value, the rate of change in protein content is not more than 20%, preferably not more than 10%, eg 7-8%, more preferably not more than 5%, 2% or 1%.
- UV ultraviolet spectrophotometry
- the stability of the liquid formulation of the present invention is checked by measuring the turbidity change of the liquid formulation of the present invention after storage, or after a shaking experiment, or after a freeze-thaw experiment, wherein, for example, by the OD350nm method, Relative to the initial value, the change value is not more than 0.06, preferably not more than 0.05, more preferably not more than 0.04, not more than 0.02.
- the stability of the liquid formulations of the present invention is checked for stability after storage, or after shaking experiments, or after freeze-thaw experiments, by measuring changes in the purity of the liquid formulations of the present invention, wherein size exclusion HPLC Chromatography (SEC-HPLC), the change in monomer purity (or the main peak change) by no more than 10% relative to the initial value, e.g. no more than 5%, 4%, 3%, e.g. no more than 2%, Preferably not more than 1%.
- SEC-HPLC size exclusion HPLC Chromatography
- the stability of the liquid formulation of the present invention is examined by measuring the change in purity of the liquid formulation of the present invention after storage, or after a shaking experiment, or after a freeze-thaw experiment, wherein by non-reduced dodecane Sodium sulfate capillary electrophoresis (CE-SDS) method, relative to the initial value, the change value (or the main peak change value) of the monomer purity decreases by not more than 10%, such as not more than 5%, 4%, 3%, 2% or 1%.
- CE-SDS dodecane Sodium sulfate capillary electrophoresis
- the stability of the liquid formulations of the present invention is tested by imaging capillary isoelectric focusing electrophoresis (iCIEF) after storage, or after shaking experiments, or after freeze-thaw experiments, wherein the antibody relative to the initial value is tested for stability
- the sum of the change values of the charge variants (principal component, acidic component and basic component) of the The change value does not exceed 20%, 15%, 10%, 8%, 5%.
- the stability of the liquid formulation of the present invention is tested by direct ELISA after storage, or after shaking experiments, or after freeze-thaw experiments, wherein the relative binding activity of the antibody is 70 relative to the initial value.
- the polysorbate 80 content is detected by high performance liquid chromatography-fluorescence detection method (HPLC-FLD method), polysorbate 80 content It should be 0.2 to 0.8 mg/ml, preferably 0.3 to 0.7 mg/ml.
- the liquid formulation of the present invention is stable after storage, for example at 25°C for at least 2 months, or at 40°C ⁇ 2°C for 1 month, preferably having one of the following characteristics or multinomial: relative to the initial value stored on day 0,
- the variation of the main peak is less than 1% as measured by SEC-HPLC method, and/or the preparation has a purity greater than 96%, preferably greater than 97%, 98%;
- the main peak change value is less than 2% as measured by non-reducing CE-SDS method, and/or the preparation has a purity of more than 96%, preferably a purity of more than 97%, 98%;
- the total change value does not exceed about 40% (for example, not more than 35%, 30%, 25%, 20%, 15%, 10%) or the principal component change value does not exceed 20% (eg, no more than 15%, 12%, 10%, 8%), or
- the sum of the change values does not exceed about 20% (eg, not more than 15%, 14%, 13%, 12%) or the principal component change value does not exceed about 15% (eg, not more than 10%) %, 8%, 7%, 6%, 5%);
- the relative binding activity of PD-L1/LAG-3 diabody protein in the preparation is 70%-130% as measured by ELISA, for example, 90, 93, 95, 98, 100, 103, 105, 108, 110, 115, 120%;
- liquid formulations of the present invention are stable after storage, for example at 5°C ⁇ 3°C for at least 6 months, preferably having one or more of the following characteristics:
- the liquid preparation of the present invention is a pharmaceutical preparation, preferably an injection, more preferably a subcutaneous injection or an intravenous injection.
- the liquid formulation is an intravenous infusion.
- the present invention provides a solid antibody preparation obtained by subjecting the liquid antibody preparation of the present invention to a solidification treatment.
- the solidification treatment is carried out by, for example, a crystallization method, a spray drying method or a freeze drying method.
- the solid antibody formulation is, for example, in the form of a lyophilized powder for injection.
- Solid antibody formulations can be reconstituted in a suitable vehicle prior to use to form a reconstituted formulation of the invention.
- the reconstituted formulation is also a liquid antibody formulation of the present invention.
- the appropriate vehicle is selected from water for injection, organic solvent for injection, including but not limited to oil for injection, ethanol, propylene glycol, etc., or a combination thereof.
- the invention provides a delivery device comprising a liquid antibody formulation or a solid antibody formulation of the invention.
- the delivery device of the invention is provided in the form of a prefilled syringe containing the liquid antibody formulation or solid antibody formulation of the invention, eg, for intravenous, subcutaneous, intradermal or intramuscular injection, intravenous infusion .
- the present invention provides a method of delivering a PD-L1/LAG-3 diabody protein to a subject, such as a mammal, comprising the step of administering to said subject a liquid antibody formulation or solid antibody formulation of the present invention,
- the delivery is effected, for example, by a delivery device using a prefilled syringe.
- the present invention provides use of the liquid antibody formulation or solid antibody formulation of the present invention for the preparation of a delivery device or prefilled syringe or a prefilled syringe that simultaneously targets LAG-3 and PD-L1 signaling pathways to treat or prevent tumors.
- a drug wherein the tumor is cancer, including but not limited to gastrointestinal cancers such as colon cancer or colorectal cancer or rectal cancer.
- the present invention also provides a method by administering to a subject a liquid antibody formulation or solid antibody formulation of the invention or a delivery device (eg, a prefilled syringe) or medicament comprising the liquid antibody formulation or solid antibody formulation, in a subject Methods of blocking the LAG-3 and/or PD-L1 signaling pathway in patients to reduce or eliminate the immunosuppressive effects of LAG-3 and/or PD-L1.
- a delivery device eg, a prefilled syringe
- medicament comprising the liquid antibody formulation or solid antibody formulation
- the invention also provides a method for treating a subject by administering to a subject a liquid antibody formulation or solid antibody formulation of the invention or a delivery device (eg, a prefilled syringe) or drug comprising the liquid antibody formulation or solid antibody formulation disease of the patient, such as the method for the above-mentioned tumor.
- a delivery device eg, a prefilled syringe
- drug comprising the liquid antibody formulation or solid antibody formulation disease of the patient, such as the method for the above-mentioned tumor.
- Fig. 1 Structure of bispecific antibody of PD-L1/LAG-3 of the present invention
- the term “comprising” or “comprising” means the inclusion of stated elements, integers or steps, but not the exclusion of any other elements, integers or steps.
- the term “comprising” or “comprising” is used, unless otherwise indicated, it also encompasses situations consisting of the recited elements, integers or steps.
- reference to an antibody variable region that "comprises” a particular sequence is also intended to encompass antibody variable regions that consist of that particular sequence.
- antibody is used in the broadest sense to refer to a protein comprising an antigen-binding site, encompassing natural and artificial antibodies of various structures, including, but not limited to, whole antibodies and antigen-binding fragments of antibodies.
- the terms “whole antibody”, “full length antibody”, “complete antibody” and “intact antibody” are used interchangeably herein to refer to a naturally occurring heavy chain (H) comprising at least two heavy chains (H) interconnected by disulfide bonds and two light chain (L) glycoproteins.
- Each heavy chain consists of a heavy chain variable region (abbreviated herein as VH) and a heavy chain constant region.
- the heavy chain constant region consists of three domains, CH1, CH2 and CH3.
- Each light chain consists of a light chain variable region (abbreviated herein as VL) and a light chain constant region.
- the light chain constant region consists of one domain, CL.
- the VH and VL regions can be further subdivided into hypervariable regions (complementarity determining regions (CDRs), with more conserved regions (framework regions (FR)) interposed therebetween.
- CDRs complementarity determining regions
- FR frame regions
- Each VH and VL consists of three CDRs and four
- the FRs are composed, from the amino terminus to the carboxy terminus, in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.
- the constant region is not directly involved in the binding of the antibody to the antigen, but exhibits various effector functions.
- antibody preparation refers to a preparation that is in a form that allows the biological activity of the antibody as the active ingredient to be effectively exerted, and that does not contain unacceptable toxicity to the subject to which the preparation is to be administered. other components. Such antibody preparations are generally sterile.
- pharmaceutically acceptable excipients are included in the antibody formulation.
- a "pharmaceutically acceptable" excipient is an agent that can reasonably be administered to a subject mammal so that an effective dose of the active ingredient used in the formulation can be delivered to the subject.
- concentration of the excipient is adapted to the mode of administration, eg, may be acceptable for injection.
- PD-L1/LAG-3 diabody preparation is also abbreviated as "antibody preparation of the present invention” herein, which means comprising PD-L1/LAG-3 diabody protein as an active ingredient and pharmaceutically acceptable excipients preparation of the agent.
- antibody preparation of the present invention means comprising PD-L1/LAG-3 diabody protein as an active ingredient and pharmaceutically acceptable excipients preparation of the agent.
- the PD-L1/LAG-3 diabody protein as an active ingredient is suitable for therapeutic or prophylactic administration to human or non-human animals.
- Antibody formulations of the invention can be prepared, for example, as liquid formulations in aqueous form, eg, ready-to-use prefilled syringes, or as lyophilized formulations by dissolving and/or suspending in a physiologically acceptable solution immediately before use Reconstitute (ie, reconstitute).
- the PD-L1/LAG-3 diabody protein formulation is in the form of a liquid formulation.
- a “stable” antibody formulation is one in which the antibody in the formulation retains an acceptable degree of physical and/or chemical stability after storage under specified conditions, or after shaking, or after repeated freeze-thaw cycles.
- antibodies contained in antibody formulations may not maintain 100% of their chemical structure after storage, shaking, or repeated freeze-thaw cycles, typically if maintained about 90%, about 95%, about 96%, about 97%, about 98% or about 99% of the structure or function of the antibody, an antibody preparation is considered “stable.”
- the PD-L1/LAG-3 diabody protein formulations of the invention exhibit low to undetectable antibody aggregation or degradation or chemical modification during manufacture, preparation, shipping, and long-term storage, thereby There is little or even no loss of biological activity of the PD-L1/LAG-3 diabody protein, showing a high degree of stability.
- the PD-L1/LAG-3 diabody protein formulation of the present invention substantially retains its physical and chemical stability after storage, shaking and/or repeated freezing and thawing.
- the liquid formulation of the present invention is stable at room temperature or at 40°C for at least 2 weeks, and/or at 25°C for at least 2 months, and/or at 2-8°C for at least 6 months.
- Stability can be measured at selected temperatures and selected storage times. For example, the storage time can be selected based on the expected shelf life of the formulation. Alternatively, accelerated stability testing can be used. In some embodiments, stability testing is performed by subjecting antibody formulations to various stress tests.
- formulated PD-L1/LAG-3 diabody protein formulations can be filled into glass vials to test antibody stability under high temperature stress.
- Antibodies can be considered to "retain their physical stability" in the formulation. Safety concerns arise as the aggregation of antibodies in the formulation can potentially lead to an increased immune response in the patient. Therefore, there is a need to minimize or prevent aggregation of antibodies in formulations.
- Light scattering methods can be used to determine visible aggregates in formulations.
- SEC-HPLC can be used to determine soluble aggregates in formulations.
- the stability of the formulation can be indicated by visually inspecting the appearance, color and/or clarity of the formulation, or by measuring the turbidity of the formulation by the OD350nm method, or by measuring the purity of the formulation by the non-reducing CE-SDS method.
- the stability of the formulation is measured by determining the percentage of antibody monomer in the formulation after storage at a specific temperature for a specific time or after shaking or after repeated freeze-thaw cycles, wherein the percentage of antibody monomer in the formulation The higher, the higher the stability of the formulation.
- an "acceptable level" of physical stability may mean that at least about 90% of the PD-L1/LAG-3 diabody monoclonal antibody is detected in the formulation after storage at a specified temperature for a specified period of time, after shaking or after repeated freezing and thawing body.
- An acceptable degree of physical stability indicates an acceptable degree of physical stability after months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, at least 12 months, at least 18 months, at least 24 months or more At least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% of PD-L1/LAG-3 double-antibody protein monomers.
- the particular temperature at which the pharmaceutical formulation is stored can be any temperature from about -80°C to about 45°C, eg, at about -80°C, about -30°C, about -20°C, about 0°C, About 4°C-8°C, about 5°C, about 25°C, about 35°C, about 37°C, about 40°C, about 42°C, or about 45°C.
- the drug formulation is considered stable.
- the pharmaceutical preparation is considered to be stable. If stored at about 5°C for 6 months, at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% PD-L1/LAG detected -3 double antibody protein monomer, the pharmaceutical preparation is considered to be stable. If stored at about 5°C for 6 months, at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% PD-L1/LAG detected -3 double antibody protein monomer, the pharmaceutical preparation is considered to be stable.
- An antibody in a formulation may be considered to "retain its chemical stability" if the antibody in the formulation does not show significant chemical changes after a period of storage, or after a period of shaking, or after repeated freeze-thaw cycles.
- Most chemical instability results from the formation of covalently modified forms of the antibody (eg, charge variants of the antibody).
- charge variants of the antibody e.g., charge variants of the antibody.
- chemical stability can be assessed by detecting and/or quantifying chemically altered forms of the antibody.
- charge variants of the antibody in the preparation can be detected by cation exchange chromatography (CEX) or imaging capillary isoelectric focusing electrophoresis (iCIEF).
- CEX cation exchange chromatography
- iCIEF imaging capillary isoelectric focusing electrophoresis
- the stability of the formulation is measured by determining the percent change in the charge variant of the antibody in the formulation after storage at a specific temperature for a specific time or after shaking or multiple freeze-thaw cycles, wherein the smaller the change , the higher the stability of the formulation.
- An "acceptable level" of chemical stability can be expressed in terms of charge variants (such as principal or acidic components or bases) in a formulation after storage at a specified temperature for a specified period of time, or after a period of shaking, or after repeated freeze-thaw cycles.
- the percentage change value of the chemical component does not exceed 40%, such as not more than 30%, not more than 20%; or the sum of the percentage change value of the charge variants (main component, acidic component and basic component) does not exceed 60% , such as not more than 50%, not more than 30%; or the main component content is not less than 50%, such as not less than 60%, not less than 70%.
- an acceptable level of chemical stability may Indicates that the percent change in charge variants of the principal component does not exceed about 50%, 40%, 30%, 20%, or 15%; or the sum of the percent change in charge variants does not exceed about 60%, 50%, or 30 %.
- the temperature at which the pharmaceutical formulation is stored can be any temperature from about -80°C to about 45°C, eg, at about -80°C, about -30°C, about -20°C, about 0°C, about 4°C-8°C, about 5°C, about 25°C or about 45°C.
- the pharmaceutical formulation can be considered stable.
- the pharmaceutical formulation can also be considered stable. If after 1 month of storage at 40°C, the percent change in principal component charge variants is less than about 50%, 40%, 30%, 20%, 16%, 15%, 14%, 13%, 12%, 10%, 5% or 4%, the pharmaceutical formulation can also be considered stable.
- lyophilized formulation refers to a composition obtained or obtainable by lyophilization of a liquid formulation. Preferably, it is a solid composition with a water content of less than 5%, preferably less than 3%.
- reconstituted formulation refers to a liquid formulation obtained by dissolving and/or suspending a solid formulation (eg, a lyophilized formulation) in a physiologically acceptable solution.
- room temperature refers to a temperature of 15°C to 30°C, preferably 20°C to 27°C, more preferably 25°C.
- Stress conditions refers to chemically and/or physically unfavorable environments for an antibody protein that can lead to unacceptable destabilization of the antibody protein, eg, high temperature, shaking, freezing and thawing.
- High temperature stress refers to the storage of antibody preparations at room temperature or even at higher temperatures (eg, 40°C ⁇ 2°C) for a period of time. The stability of the antibody preparation can be checked by a high temperature stress accelerated test.
- parenteral administration means administration other than enteral and topical administration, usually by injection or infusion, and includes, but is not limited to, intravenous, intramuscular, intraarterial, intrathecal , intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural and intrasternal injection and infusion .
- the stable PD-L1/LAG-3 dual antibody protein formulations of the invention are administered parenterally to a subject.
- the PD-L1/LAG-3 dual antibody protein formulation of the present invention is administered to a subject by subcutaneous, intradermal, intramuscular or intravenous injection.
- the present invention provides stable liquid antibody formulations comprising (i) a PD-L1/LAG-3 diabody, (ii) a buffer, (iii) a stabilizer, and (iv) a surfactant.
- the pH of the antibody formulation is about 5.5-6.5.
- the liquid antibody formulation further comprises (v) a chelating agent.
- the liquid antibody formulation of the present invention is in the form of an injectable formulation.
- the PD-L1/LAG-3 diabody in the antibody preparation of the present invention is the bispecific antibody IGN-LP disclosed in PCT Application No. PCT/CN2020/073964 (International Application Date: January 23, 2020).
- the PD-L1/LAG-3 double antibody is produced by recombinant expression in CHO cells or HEK293 cells.
- the antibody in the liquid formulation of the present invention exhibits significant anti-tumor activity.
- administration of the antibody formulations of the present invention can produce significant tumor suppressive effects.
- the amount of antibody or antigen-binding fragment thereof contained in the antibody formulation of the invention can vary depending on the specific intended properties of the formulation, the specific environment, and the specific purpose for which the formulation is used.
- the antibody formulation is a liquid formulation, which may contain about 10-200 mg/ml, preferably about 20-100 mg/mL, eg, about 20, 25, 30, 35, 40, 45, 50, 55, 60 , 70, 80, 90 or 100 mg/ml PD-L1/LAG-3 double antibody, preferably the concentration of PD-L1/LAG-3 double antibody is about 20-60 mg/ml, more preferably about 20-30 mg/ml.
- a buffer is an agent that can maintain the pH of a solution within an acceptable range.
- the buffers used in the formulations of the present invention can control the pH of the formulations of the present invention in a pH range of about 5.5-6.5.
- the formulations of the present invention comprise a buffer system selected from the group consisting of: histidine-histidine hydrochloride buffer system, citric acid-sodium citrate buffer system, acetic acid-sodium acetate buffer system, phosphate buffer system , preferably histidine-histidine hydrochloride buffer system.
- the buffer used in the formulations of the present invention is a histidine buffer, especially a buffer system consisting of histidine and histidine hydrochloride.
- Suitable stabilizers for use in the present invention may be selected from sugars, polyols and amino acids and combinations thereof.
- Sugars for use as stabilizers include, but are not limited to, sucrose, trehalose, maltose, and combinations.
- Polyols for use as stabilizers include, but are not limited to, sorbitol, mannitol, or combinations thereof.
- Amino acids for use as stabilizers include, but are not limited to, arginine, arginine hydrochloride, methionine, glycine, proline, and combinations.
- the liquid formulation of the present invention contains arginine as a stabilizer.
- the liquid formulation of the present invention comprises a combination of arginine and sorbitol as a stabilizer.
- the liquid formulation of the present invention contains sucrose as a stabilizer.
- the liquid formulation of the present invention comprises a combination of sucrose and arginine as a stabilizer.
- the arginine is arginine hydrochloride.
- surfactant refers to organic substances that have an amphiphilic structure; that is, they are composed of groups of opposite solubility tendencies, usually an oil-soluble hydrocarbon chain and a water-soluble ionic group group.
- the surfactant in the liquid formulation of the present invention is a nonionic surfactant, eg, an alkyl poly(ethylene oxide).
- Particular nonionic surfactants that can be included in the formulations of the present invention include, for example, polysorbates such as polysorbate-20, polysorbate-80, polysorbate-60, or polysorbate-40; polox Sham et al.
- polysorbate-80 is included as a surfactant in the liquid formulation of the present invention.
- surfactants that can be used in the liquid formulations of the present invention include, but are not limited to, polysorbate surfactants (eg, polysorbate 80, polysorbate 20), poloxamers, and polyethylene glycol.
- the amount of surfactant contained in the antibody formulation of the invention can vary depending on the specific intended nature of the formulation, the specific environment, and the specific purpose for which the formulation is used.
- excipients are optionally included in the antibody liquid formulation of the present invention.
- excipients include, for example, antimicrobial agents, antistatic agents, antioxidants, chelating agents, gelatin, and the like.
- excipients and/or additives suitable for use in the formulations of the present invention are well known in the art, and are listed, for example, in "The Handbook of Pharmaceutical Excipients, 4th Ed., Rowe et al., American Pharmaceuticals Association (2003); and Remington: the Science and Practice of Pharmacy, 21st Ed. Gennaro ed. Lippincott Williams & Wilkins (2005)”.
- chelating agent refers to the ability to form a chelate with a central atom, the stability of the complex being greatly increased due to the formation of the chelate.
- the chelating compound in the liquid formulation of the present invention is a carboxylic acid type chelating agent.
- the chelating agent is selected from the group consisting of disodium edetate, aminotriacetic acid, diethylenetriaminepentaacetic acid, citric acid, tartaric acid, gluconic acid, hydroxyethylethylenediaminetriacetic acid, diethylenediamine Hydroxyethylglycine.
- the chelating agent is selected from disodium edetate.
- the present invention provides a stable formulation comprising PD-L1/LAG-3 diabody protein.
- the PD-L1/LAG-3 diabody proteins used in the formulations of the present invention can be prepared using techniques known in the art for producing antibodies.
- antibodies can be produced recombinantly.
- the antibodies of the invention are recombinantly produced in 293 cells or CHO cells.
- recombinantly produced monoclonal antibodies can be purified using conventional purification methods to provide drug substance with sufficient reproducibility and modest purity for formulation of antibody preparations.
- the supernatant from the expression system can be concentrated using a commercially available protein concentration filter such as Amicon's ultrafiltration device.
- purification of the antibody can be performed using, for example, chromatography, dialysis, and affinity purification.
- Protein A is suitable as an affinity ligand for the purification of IgG1, IgG2 and IgG4 type antibodies.
- Other antibody purification methods, such as ion exchange chromatography can also be used. After obtaining the antibody of sufficient purity, preparations comprising the antibody can be prepared according to methods known in the art.
- the fermentation broth is centrifuged to remove impurities such as cells to obtain a supernatant;
- affinity chromatography for example, specific for IgG1, IgG2 and IgG4 antibodies
- virus inactivation can be used.
- purification generally, CEX cation exchange chromatography can be used
- virus filtration to make the virus titer
- ultrafiltration/diafiltration can be used to replace the protein in a formulation buffer that is conducive to its stability and concentrate to a suitable concentration for injection). See, eg, B. Minow, P. Rogge, K. Thompson, BioProcess International, Vol. 10, No. 6, 2012, pp. 48-57.
- Biological product stability studies generally include real-time stability studies (long-term stability studies) under actual storage conditions, accelerated stability studies, and forced-condition test studies. Stability research should explore and optimize the research conditions according to the research purpose and the characteristics of the product itself; for various influencing factors (such as temperature, repeated freezing and thawing, vibration, etc.), formulate long-term, accelerated and/or forced condition tests and other stability studies plan. Accelerated and forced condition tests are useful for understanding product stability under short-term deviations from storage conditions and extreme conditions, and to provide supporting data for the determination of expiration dates and storage conditions.
- antibodies may aggregate, degrade, or chemically modify, resulting in antibody heterogeneity (including size and charge heterogeneity), aggregates and fragments, etc. Affect the quality of antibody preparations. Therefore, it is necessary to monitor the stability of antibody preparations.
- the purity of antibody preparations and the level of antibody aggregation can be assessed by methods such as reduced CE-SDS, non-reduced CE-SDS, and SEC-HPLC; capillary isoelectric focusing (cIEF), imaging capillary isoelectric Analysis of charge variants in antibody preparations by focused electrophoresis (iCIEF) and ion exchange chromatography (IEX), among others.
- the stability of the formulation can be quickly judged by visually inspecting the appearance of the formulation.
- the turbidity change of the formulation can also be detected using the OD350nm method, which can give information on the amount of soluble and insoluble aggregates.
- ultraviolet spectrophotometry UV method
- UV method ultraviolet spectrophotometry
- the antibody preparation of the present invention comprising the PD-L1/LAG-3 double anti-protein of the present invention is used for preventing or treating diseases, such as autoimmune diseases, inflammatory diseases, infections, tumors and the like.
- diseases such as autoimmune diseases, inflammatory diseases, infections, tumors and the like.
- the disease is a tumor (eg, cancer) or an infection.
- the tumor is tumor immune escape.
- a tumor such as colon cancer or colorectal cancer or rectal cancer.
- the present invention also provides the use of the formulation of the present invention in the preparation of a medicament, wherein the medicament is used to deliver PD-L1/LAG-3 double antibody protein to mammals.
- the present invention also provides a method of using the formulations of the present invention for the treatment or prevention of one or more of the aforementioned diseases and disorders.
- the mammal is a human.
- the antibody formulations of the invention can be administered to a subject or patient in a variety of ways.
- administration can be by infusion or by syringe.
- the present invention provides a delivery device (eg, a syringe) comprising an antibody formulation of the present invention (eg, a prefilled syringe).
- the patient will receive an effective amount of the PD-L1/LAG-3 diabody protein as the main active ingredient, ie, an amount sufficient to treat, ameliorate or prevent the disease or disorder of interest.
- N/A means not applicable.
- the detection items during the whole research process mainly include: (1) detection of appearance and presence of visible foreign matter; (2) determination of protein content in preparations by ultraviolet method (UV method); (3) detection of turbidity of preparations by OD350nm method; ( 4) Determine the purity of the antibody preparation by size exclusion high performance liquid chromatography (SEC-HPLC), expressed as the percentage of the area of the main peak accounting for the sum of all peak areas; (5) through a non-reducing sodium dodecyl sulfate capillary The purity of the antibody preparation was determined by electrophoresis (non-reducing CE-SDS), expressed as the percentage of the area of the main peak to the sum of all peak areas; (6) The charge variant in the antibody preparation was determined by the iCIEF method, expressed as the main component, the acid group (7) Determination of the relative binding activity of PD-L1/LAG-3 double antibody to PD-L1 and LAG-3 antigens in antibody preparations by direct ELISA assay or luciferase reporter gene cells Assays
- the protein content in the samples was determined using an ultraviolet spectrophotometer (manufactured by Shimadzu, Japan, model UV-1800) or a multi-channel microspectrophotometer (manufactured by Thermo, USA, model Nanodrop 8000).
- the mobile phase is phosphate buffer (weigh 3.12g sodium dihydrogen phosphate dihydrate, 8.77g sodium chloride and 34.84g arginine, dissolve in ultrapure water and adjust the pH to 6.8 with hydrochloric acid and dilute to 1000ml), the column protection solution is 0.05% (w/v) NaN3, the injection volume is 50 ⁇ l, the flow rate is 0.5ml/min, the collection time is 30 minutes, the column temperature is 25°C, and the detection wavelength is 280nm.
- phosphate buffer weigh 3.12g sodium dihydrogen phosphate dihydrate, 8.77g sodium chloride and 34.84g arginine, dissolve in ultrapure water and adjust the pH to 6.8 with hydrochloric acid and dilute to 1000ml
- the column protection solution is 0.05% (w/v) NaN3
- the injection volume is 50 ⁇ l
- the flow rate is 0.5ml/min
- the collection time is 30 minutes
- the column temperature is 25°C
- the detection wavelength is 280
- sample diluent (0.85mg/ml histidine, 0.97mg/ml histidine hydrochloride, 35.11mg/ml arginine hydrochloride, 0.01mg/ml disodium edetate, 0.10mg/ml polyamide Sorbitan 80) diluted to 2mg/ml, as the test solution.
- the preparation buffer was diluted in the same way as above and used as blank solution. Take 50 ⁇ l of blank solution and 50 ⁇ l of test solution and inject into liquid chromatograph to start detection.
- the capillary is an uncoated capillary with an inner diameter of 50 ⁇ m, a total length of 30.2 cm, and an effective length of 20.2 cm.
- the capillary column was washed with 0.1 mol/L sodium hydroxide, 0.1 mol/L hydrochloric acid, ultrapure water, and electrophoresis gel at 70 psi, respectively.
- the sample to be tested was diluted to 0.6 mg/ml with a pH 6.5 diluent (200 ⁇ l of pH 6.5 citric acid-phosphate buffer was added to 400 ⁇ l of 10% sodium dodecyl sulfate, and water was added to make up to 1 ml).
- Imaging capillary isoelectric focusing electrophoresis was used for detection.
- the inner diameter of the capillary is 100 ⁇ m and the total length is 5 cm.
- the sample was diluted to 1.0mg/ml with 3mol/L urea-0.5%MC (hydroxymethyl cellulose) solution, 70 ⁇ l of 3mol/L urea-0.5%MC solution, 3 ⁇ l of ampholyte (pH 3 ⁇ 10), pI 5.85, 9.46 Maker (isoelectric point marker) 0.3 ⁇ l each, 5mol/L NDSB (3-[(2-hydroxyethyl)dimethylamino]propane-1-sulfonate) 5 ⁇ l, 0.5mol/L Taurine (bovine) sulfonic acid) 2 ⁇ l, final sample concentration 0.2 mg/ml, focusing voltage 3 kV, focusing time 5 minutes.
- the blank solution was prepared by the same method using the preparation buffer.
- the SA protein was diluted with PBS (phosphate buffered saline) to 1.0 ⁇ g/ml, 100 ⁇ l/well, incubated at 37° C. for 2 hours, and the protein was coated on a 96-well microtiter plate. After washing the plate, add blocking solution (2% BSA-PBST, 300 ⁇ l/well), and block at 37° C. for 2 hours. After washing the plate, Biotin LAG-3 was diluted to 0.5 ⁇ g/ml with 2% BSA-PBST (PBST: phosphate buffer + Tween 20; BSA: bovine serum albumin), and 100 ⁇ l/well was put into the ELISA plate, Wash the plate after 30 min incubation at 37°C.
- PBS phosphate buffered saline
- test sample was diluted to 40 ⁇ g/ml with 2% BSA-PBST, and the 4-fold gradient was diluted to the 12th concentration.
- HRP horseradish peroxidase
- the SA protein was diluted with PBS to 1.0 ⁇ g/ml, 100 ⁇ l/well, incubated at 37°C for 2 hours, and the protein was coated on a 96-well microtiter plate. After washing the plate, add blocking solution (2% BSA-PBST, 300 ⁇ l/well), and block at 37° C. for 2 hours. Wash the plate, dilute Biotin PD-L1 with 2% BSA-PBST to 0.5 ⁇ g/ml, put 100 ⁇ l/well into the ELISA plate, and wash the plate after incubating at 37°C for 30 minutes. The test sample was diluted to 60 ⁇ g/ml with 2% BSA-PBST, and the 4-fold gradient was diluted to the 12th concentration.
- the polysorbate 80 content of the samples to be tested was determined by HPLC-FLD method (fluorescence method).
- the chromatographic column was Knitted Reactor coil column (5m ⁇ 0.5mm ID) from SUPELCO, mobile phase: 0.15mol/L sodium chloride, 0.05mol/L Tris, pH 8.0, 5% acetonitrile, 5.0 ⁇ mol/L NPN ( N-phenyl-1-naphthylamine), 15 ppm Brij solution (polyoxyethylene (23) lauryl ether solution).
- Detection conditions flow rate 1.5ml/min, excitation wavelength 350nm, emission wavelength 420nm, column temperature 30°C, elution time 3 minutes, injection volume 10 ⁇ l.
- the content of polysorbate 80 in the finished product was calculated by the standard curve method.
- MHCII APC cells Adjust MHCII APC cells to 0.4 ⁇ 10 6 cells/ml with MHCII APC cells Assay Buffer (1% FBS (Fetal Bovine Serum, Cat. No. 10099-141), 99% DMEM-High Glucose Medium (Cat. No. 11995-040)) , dilute HA-peptide (Cat. No.: PP-1901-13) to 40 ⁇ g/ml, mix the two in equal volumes 1:1, inoculate 100 ⁇ l/well in a 96-well cell culture plate according to the experimental layout, and culture overnight (18-22h). ).
- Jurkat-LAG-3-NFAT-Luc2 was adjusted with LAG-3 Effector cells Assay Buffer (1% FBS (Fetal Bovine Serum, Cat. No.
- DMEM-High Glucose Medium (Cat. No. 11995-040)) (Cat. No. CS194812) to 3.0 ⁇ 10 6 cells/ml; dilute the sample to 80.00 ⁇ g/ml, and then dilute 4-fold gradient, with a total of 10 concentration points (0.3ng/ml ⁇ 80000ng/ml).
- the medium in the 96-well plate was aspirated, and the treated samples and Jurkat-LAG-3-NFAT-Luc2 cells (40 ⁇ l/well, respectively) were added, and the culture was continued for 7 h.
- CHOK1-PDL1 (Cat. No. CS187108) cells to 0.3 ⁇ 10 6 cells/ml with Assay Buffer (10% fetal bovine serum, 90% RPMI1640 medium (Cat. No.: SH30809.01)), and seed 100 ⁇ l/well in 96 cells according to the experimental layout Well culture plate, adherent culture for 16 ⁇ 20h.
- Assay Buffer 10% fetal bovine serum, 90% RPMI1640 medium (Cat. No.: SH30809.01)
- Jurkat-NFAT-Luc2/PD1 (Cat. No. CS187102) cells to 0.6 ⁇ 10 6 cells/ml with Assay Buffer, dilute the sample to 12.00 ⁇ g/ml, 2.6-fold gradient dilution, a total of 10 concentration points (2.2ng/ml ⁇ 12000ng /ml).
- the medium in the 96-well plate was aspirated, and the treated samples and Jurkat-NFAT-Luc2/PD1 cells (40 ⁇ l/well, respectively) were added, and the culture was continued for 6 h. After the cell culture plate was equilibrated to room temperature, 80 ⁇ l of Bio-Glo TM Luciferase Assay System chromogenic solution (equilibrated to room temperature in advance) was added to each well, and the reaction was carried out for 10 min. Using the software of the Max i3 microplate reader, according to the established layout, set the reading program to read the chemiluminescence value of the full wavelength.
- the four-parameter fitting curve of the GraphPad Prism software was used to calculate the ratio of the EC50 of the reference product to the EC50 of the sample, reflecting the biological activity of the anti-PD-L1 end of the sample to be tested.
- PCT/CN2020/073964 the bispecific antibody IGN-LP that binds both PD-L1 and LAG-3 was obtained.
- PCT Application No. PCT/CN2020/073964 is hereby incorporated by reference in its entirety.
- antibodies were recombinantly expressed in HEK293 cells and purified by filtration, chromatography, virus inactivation, filtration, and the like.
- a total of 4 prescriptions were designed, and the detailed prescription information is shown in Table 1.
- the buffers for each formulation were prepared, and the purified bispecific antibody protein of the invention of Example 1 was ultrafiltered into the respective formulation solution. After displacement was complete, each formula protein concentration was diluted to about 20 mg/ml and polysorbate 80 was added. Filter and pack into vials, stoppered and capped, and conduct stability inspection.
- the test items are appearance, visible foreign matter, protein content (UV method), turbidity (OD350nm method), polysorbate 80 content (HPLC-FLD method), purity (SEC-HPLC method and non-reducing CE-SDS method), Charge variants (iCIEF method) and relative binding activity (direct ELISA method).
- the prescription screening experiment used the criteria shown in Table 3 to judge the quality
- formula 1 was selected to conduct a pilot-scale long-term stability investigation.
- prescription 1 (20.0mg/ml recombinant anti-lymphocyte activation gene-3 (LAG-3) and anti-programmed death ligand 1 (PD-L1) bispecific antibody, 0.85mg/ml histidine acid, 0.97mg/ml histidine hydrochloride, 35.11mg/ml arginine hydrochloride, 0.01mg/ml disodium edetate, 0.50mg/ml polysorbate 80, pH 5.8-6.4) to produce 3 batches of finished preparations,
- the long-term stability was investigated at 5°C ⁇ 3°C, and the samples were sampled at 0, 3, and 6 months. The results are shown in Table 6. The results showed that the protein in the formulation was stable, and there was no significant difference between batches, which was in line with the actual production process quality standards.
- PD-L1 transgenic mice (MC38-huPD-L1 KI tumor-bearing mouse model, referred to as MC38/PD-L1 model) inoculated with MC38-huPD-L1 KI (MJ-1) colon cancer cells were used to determine the anti-bacterial effect of the present invention.
- Antitumor effect of LAG-3/PD-L1 bispecific antibody IGNLP ie, IGN-LP prepared as described in Example 1).
- the MC38-huPD-L1 KI tumor-bearing mouse model was established by subcutaneous inoculation. After tumor formation, the mice were divided into groups and treated with different antibodies. The tumor volume and body weight of the mice in each group were monitored during the administration period. The administration frequency was 2 times/day. Week, 2 weeks of administration, a total of 5 doses. The monitoring frequency was 2 times/week, and the monitoring was performed continuously for 4 weeks.
- the dosage and method of administration were as follows.
- TGI% 100%*(tumor volume in the h-IgG control group – tumor volume in the treatment group)/(tumor volume in the h-IgG control group – h- The tumor volume of the IgG control group before administration), wherein the average tumor volume of the h-IgG control group before administration was 80 mm 3 .
- mice PD-L1 transgenic mice, female, 7-8 weeks (the mouse age at the time of tumor cell inoculation), body weight 18-20 g, purchased from Shanghai Southern Model Biotechnology Co., Ltd. Mice were acclimated for 7 days after arrival before the study began.
- Mouse colon cancer cell MC38 (Shanghai Heyuan Biotechnology, HYC0116) was purchased from Shanghai Heyuan Biotechnology Co., Ltd. and knocked in the human PD-L1 gene (Nanjing Galaxy Biomedical Co., Ltd.) to obtain MC38 cells containing human PD-L1 , cultured in RPMI 1640 medium (Gibco, 22400-071), and routinely subcultured in strict accordance with MC38 culture requirements for subsequent in vivo experiments. Centrifugation (400g / min, 5 min) cells were harvested, the cells were resuspended in sterile RPMI 1640 basal medium and cell density was adjusted to 5 ⁇ 10 6 cells / ml.
- mice with an average tumor volume in the range of 76-80 mm 3 were selected and randomly grouped according to tumor volume.
- the anti-tumor activity of the anti-LAG-3/PD-L1 antibody alone was tested as follows.
- Anti-PD-L1 antibody humanized anti-PD-L1 antibody Nb-Fc was obtained according to the method in patent ZL201710657665.3.
- Anti-LAG-3 antibody (ADI-31853) was obtained according to the method in patent application WO2019/129137.
- mice were divided into 11 groups (6 mice in each group), and each group was subcutaneously injected with the following doses of antibodies:
- Anti-PD-L1 antibody humanized anti-PD-L1 antibody Nb-Fc), 1.25mg/kg;
- Anti-PD-L1 antibody humanized anti-PD-L1 antibody Nb-Fc, 2.5mg/kg;
- Anti-PD-L1 antibody humanized anti-PD-L1 antibody Nb-Fc, 5mg/kg;
- LAG-3 (ADI-31853), 10mg/kg + anti-PD-L1 antibody (humanized anti-PD-L1 antibody Nb-Fc), 2.5mg/kg;
- LAG-3 (ADI-31853), 10mg/kg + anti-PD-L1 antibody (humanized anti-PD-L1 antibody Nb-Fc), 5mg/kg;
- Human IgG was a human IgG preparation obtained from Equitech-Bio.
- mice in each group were dosed as above with the above antibodies, respectively.
- Tumor inhibition rate (%) Complete tumor disappearance human IgG 2411 - 0/6 Nb-Fc, 1.25mg/kg 829 68 0/6 Nb-Fc, 2.5mg/kg 1065 58 0/6 Nb-Fc, 5mg/kg 902 65 0/6
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
名称 | 序列号 |
VH-CH1-Fc-X-VHH(示例性式(I)的多肽链) | SEQ ID NO:1 |
抗LAG-3抗体VH(示例性式(I)的VH) | SEQ ID NO:2 |
CH1(示例性式(I)的CH1) | SEQ ID NO:3 |
Fc(示例性式(I)的Fc) | SEQ ID NO:4 |
接头(示例性式(I)的X) | SEQ ID NO:5 |
抗PD-L1单结构域抗体(示例性式(I)的VHH) | SEQ ID NO:6 |
VL-CL(示例性式(II)的多肽链) | SEQ ID NO:7 |
抗LAG-3抗体VL(示例性式(II)的VL) | SEQ ID NO:8 |
CL(示例性式(II)的CL) | SEQ ID NO:9 |
抗PD-L1单结构域抗体CDR1(示例性式(I)的VHH CDR1) | SEQ ID NO:10 |
抗PD-L1单结构域抗体CDR2(示例性式(I)的VHH CDR2) | SEQ ID NO:11 |
抗PD-L1单结构域抗体CDR3(示例性式(I)的VHH CDR3) | SEQ ID NO:12 |
抗LAG-3抗体HCDR1(示例性式(I)的VH的HCDR1) | SEQ ID NO:13 |
抗LAG-3抗体HCDR2(示例性式(I)的VH的HCDR2) | SEQ ID NO:14 |
抗LAG-3抗体HCDR3(示例性式(I)的VH的HCDR3) | SEQ ID NO:15 |
抗LAG-3抗体LCDR1(示例性式(II)的VL的LCDR1) | SEQ ID NO:16 |
抗LAG-3抗体LCDR2(示例性式(II)的VL的LCDR2) | SEQ ID NO:17 |
抗LAG-3抗体LCDR3(示例性式(II)的VL的LCDR3) | SEQ ID NO:18 |
抗LAG-3抗体重链(示例性式(I)的VH-CH1-Fc) | SEQ ID NO:19 |
缩略词 | 全称 |
CE-SDS | 十二烷基硫酸钠毛细管凝胶电泳 |
ELISA | 酶联免疫吸附测定 |
FLD | 荧光检测器 |
HPLC | 高效液相色谱仪 |
iCIEF | 成像毛细管等电聚焦电泳 |
SEC-HPLC | 体积排阻高效液相色谱 |
名称 | 级别 | 产地及品牌 | 货号 | 符合标准 |
组氨酸 | 药用级 | 上海味之素 | N/A | Ch.P(2015年版),USP |
盐酸组氨酸 | 药用级 | 上海味之素 | N/A | Ch.P(2015年版) |
山梨醇 | 药用级 | 法国罗盖特 | H20110265 | EP,BP,NF,USP |
依地酸二钠 | 药用级 | 美国 Avantor | 8995-01 | EP,BP,JP,USP |
蔗糖 | 药用级 | 德国 Merck | 1.00892.9050 | Ch.P(2015年版),USP |
盐酸精氨酸 | 药用级 | 上海味之素 | N/A | Ch.P(2015年版),USP |
聚山梨酯80 | 药用级 | 南京威尔 | 苏药准字F15423203 | Ch.P(2015年版) |
囊式滤器H4 | N/A | 德国 Sartorius | 5441307H4-OO | N/A |
白金硅胶管 | N/A | 美国 Nalgene | 8600-0080 | N/A |
6R西林瓶 | N/A | 苏州 Schott | 1142196 | N/A |
20mm胶塞 | N/A | 新加坡 West | 7002-2354 | N/A |
20mm铝塑盖 | N/A | 新加坡 West | 5420-1035 | N/A |
名称 | 产地及品牌 | 型号 | 编号 |
电子天平 | 德国 Sartorius | BSA3202S | PD-A1-186 |
电子天平 | 瑞士 梅特勒 | XPE3003S | PD-A1-247 |
恒温恒湿箱 | 德国 BINDER | KBF P 720 | PD-A1-070 |
生化培养箱 | 上海 精宏 | SHP-150 | PD-A1-200 |
医用冷藏箱 | 青岛 海尔 | HYC-360 | PD-A1-166 |
医用冷藏箱 | 青岛 海尔 | HYC-360 | PD-A1-165 |
超低温冰箱 | 美国 Thermo | 907 | PD-A1-175 |
澄明度检测仪 | 天津 天大天发 | YB-2 | PD-A1-033 |
紫外可见分光光度计 | 日本 岛津 | UV-1800 | AS-A1-037 |
名称 | 产地及品牌 | 型号 | 编号 |
pH计 | 瑞士 梅特勒 | FE20 | PD-A1-161 |
多通道微量分光光度计 | 美国 Thermo | Nanodrop 8000 | PD-A1-052 |
台式冷冻离心机 | 美国 Thermo | SL16R | PD-A1-082 |
洁净工作台 | 苏州 Airtech | SW-CJ-2FD | QC-A1-011 |
中流量手动蠕动泵 | 英国 Watson Marlow | 520S/R2 | PD-A1-235 |
灌装机 | 丹麦 Watson Marlow | FP50 | PD-C14-115 |
不溶性微粒检测仪 | 天津 天大天发 | GWJ-8 | QC-A1-094 |
实验名称 | 处方 | 实验方案及取样点 |
40℃稳定性考察 | 处方1~处方4 | 40℃±2℃条件下放置,于0天、1周、2周和1个月取样 |
25℃稳定性考察 | 处方1~处方4 | 25℃±2℃条件下放置,于1个月和2个月取样 |
检测项目 | 质量标准 |
外观(观察法) | 澄明至微乳光,无色至微黄色液体,无异物 |
可见异物(可见异物检查法) | 符合《中华人民共和国药典》(2015年版,四部)0904[1] |
蛋白含量(UV法) | 变化率≤10% |
聚山梨酯80含量(HPLC-FLD法) | 应为0.3~0.7mg/ml |
浊度(OD 350nm法) | 变化值≤0.02 |
纯度(SEC-HPLC法) | 主峰纯度变化值≤1% |
纯度(非还原型CE-SDS法) | 主峰变化值≤2% |
相对结合活性(直接ELISA法) | 应为70%~130% |
组别 | 肿瘤体积 | 肿瘤抑制率(%) | 肿瘤完全消失数目 |
人IgG | 2411 | - | 0/6 |
Nb-Fc,1.25mg/kg | 829 | 68 | 0/6 |
Nb-Fc,2.5mg/kg | 1065 | 58 | 0/6 |
Nb-Fc,5mg/kg | 902 | 65 | 0/6 |
ADI-31853 | 2942 | - | 0/6 |
ADI-31853+Nb-Fc,1.25mg/kg | 705 | 73 | 0/6 |
ADI-31853+Nb-Fc,2.5mg/kg | 1248 | 50 | 0/6 |
ADI-31853+Nb-Fc,5mg/kg | 1198 | 52 | 0/6 |
IGNLP,3mg/kg | 151 | 97 | 2/6 |
IGNLP,6mg/kg | 367 | 88 | 0/6 |
IGNLP,12mg/kg | 500 | 82 | 1/6 |
Claims (21)
- 一种液体抗体制剂,包含(i)PD-L1/LAG-3双抗蛋白;(ii)缓冲剂,(iii)稳定剂,和(iv)表面活性剂其中所述PD-L1/LAG-3双抗蛋白包含以下部分或由其组成:(a)式(I)的多肽链:VH-CH1-Fc-X-VHH;和(b)式(II)的多肽链:VL-CL;其中:VH表示重链可变区;CH表示重链恒定区;Fc包含CH2、CH3,以及任选的CH4;CH1、CH2、CH3和CH4分别表示重链恒定区的结构域1、2、3和4;X可以不存在,或者在存在时表示接头;VHH表示单结构域抗原结合位点;VL表示轻链可变区;CL表示轻链恒定区;任选地,CH1和Fc之间存在铰链区;其中所述VHH包含SEQ ID NO:6中所含的三个互补决定区域(VHH CDR);和/或,所述VH包含如SEQ ID NO:2所示的重链可变区VH的3个互补决定区HCDR;和/或,所述VL包含如SEQ ID NO:8所示的重链可变区VL的3个互补决定区LCDR;优选地,所述液体抗体制剂还包含(v)螯合剂;优选地,所述液体抗体制剂的pH约为5.8-6.4,例如,pH为6.0±0.2或6.2±0.2,优选地pH约为6.0。
- 根据权利要求1所述的液体抗体制剂,特征在于所述液体抗体制剂中的PD-L1/LAG-3双抗蛋白的浓度为约10-200mg/ml,优选地为约20-100mg/ml,例如为约20、25、30、35、40、45、50、55、60、70、80、90或100mg/ml。
- 根据权利要求1或2所述的液体抗体制剂,特征在于,所述液体抗体制剂包含选自组氨酸-盐酸组氨酸缓冲体系;优选地,所述缓冲剂的浓度为约5-50mM,优选地为约5-30mM,例如,约5、10、15、20、25、30mM。
- 根据权利要求1-3中任何一项所述的液体抗体制剂,特征在于所述稳定剂选自多元醇(例如,山梨醇、甘露醇及其组合)、糖类(例如,蔗糖、海藻糖、麦芽糖及其组合)、氨基酸(例如精氨酸、盐酸精氨酸甲硫氨酸甘氨酸脯氨酸及组合)、和它们的任意组合,例如,所述稳定剂包含选自以下之一或多项:-选自山梨醇、甘露醇、或其组合的多元醇;-选自蔗糖、海藻糖、麦芽糖、或其组合的糖类;-选自盐酸精氨酸、甲硫氨酸、甘氨酸、脯氨酸及组合的氨基酸。
- 根据权利要求1-4中任何一项所述的液体抗体制剂,特征在于所述稳定剂包含:(i)约为120-200mM的精氨酸,优选约150-180mM,例如150、155、160、165、170、175、180mM,或(ii)山梨醇和精氨酸的组合,所述精氨酸约为60-100mM,优选约70-90mM,例如70、75、80、85、90mM;所述山梨醇约为10-30mg/ml,优选约15-25mg/ml,例如15、16、17、18、19、20、21、22、23、24、25mg/ml,或(iii)约为60-100mg/ml的蔗糖,优选约70-90mg/ml,例如70,75,80,85,90mg/ml,或(iv)蔗糖和精氨酸的组合,所述精氨酸约为60-100mM,优选约70-90mM,例如70、75、80、85、90mM;所述蔗糖约为20-60mg/ml,优选约35-45mg/ml,例如35、36、37、38、39、40、41、42、43、44、45mg/ml,优选地,所述精氨酸为盐酸精氨酸。
- 根据权利要求1-5中任何一项所述的液体抗体制剂,特征在于所述液体抗体制剂中的表面活性剂选自聚山梨酯类表面活性剂、泊洛沙姆、聚乙二醇或其组合,优选为聚山梨酯-80。
- 根据权利要求1-6中任何一项所述的液体抗体制剂,特征在于所述表面活性剂的浓度为约0.1-1mg/ml,优选地为约0.2-0.8mg/ml,例如约0.2、0.3、0.4、0.5、0.6、0.7、0.8mg/ml。
- 根据权利要求1-7中任何一项所述的液体抗体制剂,特征在于所述螯合剂是羧酸型螯合剂,优选为依地酸二钠。
- 根据权利要求1-8中任何一项所述的液体抗体制剂,特征在于所述螯合剂浓度为约0.008-0.018mg/ml,例如约0.008、0.009、0.010、0.012、0.014、0.018mg/ml。
- 根据权利要求1-9中任何一项所述的液体抗体制剂,特征在于所述VHH包含互补决定区域(CDR)VHH CDR1、VHH CDR2和VHH CDR3;其中所述VHH CDR1包含SEQ ID NO:10的氨基酸序列,或由所述氨基酸序列组成;所述VHH CDR2包含SEQ ID NO:11的氨基酸序列,或由所述氨基酸序列组成;所述VHH CDR3包含SEQ ID NO:12的氨基酸序列或由所述氨基酸序列组成;和/或,所述VH包含互补决定区域(CDR)HCDR1、HCDR2和HCDR3,其中HCDR1包含SEQ ID NO:13的氨基酸序列,或由所述氨基酸序列组成;HCDR2包含SEQ ID NO:14的氨基酸序列,或由所述氨基酸序列组成;HCDR3包含SEQ ID NO:15的氨基酸序列,或由所述氨基酸序列组成;和/或,所述VL包含互补决定区域(CDR)LCDR1、LCDR2和LCDR3,其中LCDR1包含SEQ ID NO:16的氨基酸序列,或由所述氨基酸序列组成;LCDR2包含SEQ ID NO:17的氨基酸序列,或由所述氨基酸序列组成;LCDR3包含SEQ ID NO:18的氨基酸序列,或由所述氨基酸序列组成。
- 根据权利要求1-10中任何一项所述的液体抗体制剂,特征在于所述VHH包含如SEQ ID NO:6所示的序列或由其组成;和/或,所述VH包含如SEQ ID NO:2所示的氨基酸序列或由其组成;和/或,所述VL包含如SEQ ID NO:8所示的氨基酸序列或由其组成。
- 根据权利要求1-11中任何一项所述的液体抗体制剂,特征在于所述式(I)中的VH-CH1-Fc包含SEQ ID NO:19的氨基酸序列或由其组成;和/或,所述的式(II)中的VL-CL包含SEQ ID NO:7的氨基酸序列或由其组成;较佳地:所述的式(I)的多肽链包含SEQ ID NO:1所示的序列或由其组成;和/或,所述的式(II)的多肽链包含SEQ ID NO:7所示的序列或由其组成。
- 根据权利要求1-12中任何一项所述的液体抗体制剂,特征在于所述PD-L1/LAG-3双抗在HEK293细胞或CHO细胞中重组表达。
- 根据权利要求1-13中任何一项所述的液体抗体制剂,特征在于所述液体制剂为注射剂,优选用于皮下注射或静脉内注射,或者为输注剂,例如用于静脉内输注。
- 根据权利要求1-14中任一项所述的液体抗体制剂,其包含:(i)约20-100mg/ml的PD-L1/LAG-3双抗蛋白;(ii)约5-30mM的组氨酸缓冲剂;(iii)约150-180mM的精氨酸;或山梨醇和精氨酸的组合,所述精氨酸约为60-100mM,所述山梨醇约为10-30mg/ml;或约60-100mg/ml的蔗糖;或蔗糖和精氨酸的组合,所述精氨酸约为60-100mM,所述蔗糖约为20-60mg/ml;(iv)约0.2-0.8mg/ml聚山梨酯80;和(v)约0.008-0.018mg/ml依地酸二钠,其中所述液体制剂的pH为约5.8-6.4;或者,所述液体抗体制剂包含(i)约20-60mg/ml的PD-L1/LAG-3双抗蛋白;(ii)约5-15mM的组氨酸缓冲剂;(iii)约160-170mM的精氨酸;或山梨醇和精氨酸的组合,所述精氨酸约为70-90mM,所述山梨醇约为15-25mg/ml;或约70-90mg/ml的蔗糖;或蔗糖和精氨酸的组合,所述精氨酸约为70-90mM,所述蔗糖约为35-45mg/ml;(iv)约0.3-0.6mg/ml聚山梨酯80;和(v)约0.008-0.018mg/ml依地酸二钠,其中所述液体制剂的pH为约5.8-6.4;或者,所述液体抗体制剂包含(i)约20mg/ml的PD-L1/LAG-3双抗蛋白,约10mM组氨酸缓冲剂,约165mM盐酸精氨酸,约0.50mg/ml聚山梨酯80,约0.01mg/ml依地酸二钠,pH约6.0;或(ii)约20mg/ml的PD-L1/LAG-3双抗蛋白,约10mM组氨酸缓冲剂,约80mM盐酸精氨酸,约23.66mg/ml山梨醇,约0.50mg/ml聚山梨酯80,约0.01mg/ml依地酸二钠,pH约6.0;或(iii)约20mg/ml的PD-L1/LAG-3双抗蛋白,约10mM组氨酸缓冲剂,约80.00mg/ml蔗糖,约0.50mg/ml聚山梨酯80,约0.01mg/ml依地酸二钠,pH约6.0;或(iv)约20mg/ml的PD-L1/LAG-3双抗蛋白,约10mM组氨酸缓冲剂,约80mM盐酸精氨酸,约42.00mg/ml蔗糖,约0.50mg/ml聚山梨酯80,约0.01mg/ml依地酸二钠,pH约6.0。
- 根据权利要求1-15中任何一项所述的液体抗体制剂,其特征在于,该制剂在储存后,例如在25℃储存至少2个月后,或在40℃±2℃储存1个月后,是稳定的,优选地具有如下特征之一或多项:(i)通过SEC-HPLC法测量,主峰变化值小于1%,和/或制剂具有大于96%的纯度,优选大于97%、98%的纯度;(ii)通过非还原型CE-SDS法测量,主峰变化值小于2%,和/或制剂具有大于95%的纯度,优选大于96%、97%的纯度;(iii)通过iCIEF法测量,相对于储存第0天的初始值,制剂中PD-L1/LAG-3双抗蛋白的各组分(主成分、酸性组分和碱性组分)的变化值总和不超过40%和/或主成分的变化值不超过20%,例如在40℃±2℃储存1个月后变化值总和不超过约40%(例如不超过30%)或主成分变化值不超过约20%(例如不超过15%),或在25℃储存2个月后变化值总和不超过约20%(例如约15%)或主成分变化值不超过约15%(例如不超过约10%);(iv)通过ELISA法测量,相对于储存第0天的初始值,制剂中PD-L1/LAG-3双抗蛋白的相对结合活性为70%-130%,例如,90%-110%;或者,在5℃±3℃储存至少6个月后,是稳定的,优选地具有如下特征之一或多项:(i)纯度,通过SEC-HPLC法测量,主峰应≥95.0%;(ii)纯度,通过非还原型CE-SDS法测量,主峰应≥90.0%;(iii)电荷变异体,通过iCIEF法测量,主成分应≥58.0%;(iv)制剂中PD-L1/LAG-3双抗蛋白的相对结合活性,通过荧光素酶报告基因细胞测定法测定,抗体结合活性应为70-130%;(v)pH值,应为5.8~6.4。
- 一种固体抗体制剂,其通过固化权利要求1-16中任何一项所述的液体抗体制剂而获得,所述固体抗体制剂例如是冻干粉针剂形式。
- 递送装置,其包含权利要求1-16中任何一项的液体抗体制剂或权利要求17的固体抗体制剂。
- 预填装注射器,其包含权利要求1-16中任何一项的液体抗体制剂或权利要求17的固体抗体制剂,用于静脉内注射或者肌内注射。
- 根据权利要求1-16中任何一项的液体抗体制剂或权利要求17的固体抗体制剂的用途,用于制备在受试者中阻断LAG-3和/或PD-L1通路以降低或消除免疫抑制作用的递送装置或预填装注射器或药物。
- 根据权利要求1-16中任何一项的液体抗体制剂或权利要求17的固体抗体制剂 的用途,用于制备在受试者中治疗或预防肿瘤的递送装置或预填装注射器或药物,例如,所述肿瘤是胃肠道癌症。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023504418A JP2023535433A (ja) | 2020-07-23 | 2021-07-22 | Pd-l1/lag-3二重特異性抗体製剤およびその調製方法ならびに使用 |
AU2021311673A AU2021311673A1 (en) | 2020-07-23 | 2021-07-22 | PD-L1/LAG-3 bispecific antibody preparation, and preparation method therefor and use thereof |
CA3189631A CA3189631A1 (en) | 2020-07-23 | 2021-07-22 | Pd-l1/lag-3 bispecific antibody formulation and preparation method therefor and use thereof |
EP21845945.1A EP4186522A1 (en) | 2020-07-23 | 2021-07-22 | Pd-l1/lag-3 bispecific antibody preparation, and preparation method therefor and use thereof |
US18/005,903 US20230287124A1 (en) | 2020-07-23 | 2021-07-22 | Pd-l1/lag-3 bispecific antibody formulation and preparation method therefor and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010720248.0 | 2020-07-23 | ||
CN202010720248 | 2020-07-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022017468A1 true WO2022017468A1 (zh) | 2022-01-27 |
Family
ID=79728522
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/107878 WO2022017468A1 (zh) | 2020-07-23 | 2021-07-22 | Pd-l1/lag-3双特异性抗体制剂及其制备方法和用途 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20230287124A1 (zh) |
EP (1) | EP4186522A1 (zh) |
JP (1) | JP2023535433A (zh) |
AU (1) | AU2021311673A1 (zh) |
CA (1) | CA3189631A1 (zh) |
TW (1) | TWI802942B (zh) |
WO (1) | WO2022017468A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022268168A1 (zh) * | 2021-06-23 | 2022-12-29 | 迈威(上海)生物科技股份有限公司 | 靶向lag-3和pd-l1的新型双特异抗体及其应用 |
WO2023185732A1 (zh) * | 2022-03-28 | 2023-10-05 | 信达生物制药(新加坡)有限公司 | 包含抗Claudin18.2和CD3双特异性抗体的制剂及其制备方法和用途 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117159703B (zh) * | 2023-11-02 | 2024-04-02 | 正大天晴(广州)医药有限公司 | 含抗lag-3抗体的药物组合物及其用途 |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104940926A (zh) * | 2014-09-25 | 2015-09-30 | 信达生物制药(苏州)有限公司 | 重组融合蛋白制剂 |
CN105435222A (zh) * | 2014-09-25 | 2016-03-30 | 信达生物制药(苏州)有限公司 | 重组融合蛋白制剂 |
CN106620691A (zh) * | 2015-11-04 | 2017-05-10 | 信达生物制药(苏州)有限公司 | 一种重组全人源抗ctla-4单克隆抗体制剂及其应用 |
CN106913869A (zh) * | 2017-03-17 | 2017-07-04 | 信达生物制药(苏州)有限公司 | 一种抗ctla‑4单克隆抗体制剂及其应用 |
CN107686520A (zh) * | 2016-08-04 | 2018-02-13 | 信达生物制药(苏州)有限公司 | 抗pd‑l1纳米抗体及其应用 |
WO2019129137A1 (zh) | 2017-12-27 | 2019-07-04 | 信达生物制药(苏州)有限公司 | 抗lag-3抗体及其用途 |
CN109970856A (zh) * | 2017-12-27 | 2019-07-05 | 信达生物制药(苏州)有限公司 | 抗lag-3抗体及其用途 |
CN109970860A (zh) * | 2017-12-27 | 2019-07-05 | 信达生物制药(苏州)有限公司 | 三链抗体、其制备方法及其用途 |
CN109970857A (zh) * | 2017-12-27 | 2019-07-05 | 信达生物制药(苏州)有限公司 | 抗pd-l1抗体及其用途 |
CN110305210A (zh) * | 2018-03-27 | 2019-10-08 | 信达生物制药(苏州)有限公司 | 新型抗体分子、其制备方法及其用途 |
CN110678484A (zh) * | 2018-08-21 | 2020-01-10 | 天境生物 | 抗pd-l1/抗lag3双特异性抗体及其用途 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3630179A2 (en) * | 2017-05-30 | 2020-04-08 | Bristol-Myers Squibb Company | Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody |
-
2021
- 2021-07-22 WO PCT/CN2021/107878 patent/WO2022017468A1/zh active Application Filing
- 2021-07-22 EP EP21845945.1A patent/EP4186522A1/en not_active Withdrawn
- 2021-07-22 TW TW110126936A patent/TWI802942B/zh active
- 2021-07-22 US US18/005,903 patent/US20230287124A1/en not_active Abandoned
- 2021-07-22 JP JP2023504418A patent/JP2023535433A/ja active Pending
- 2021-07-22 AU AU2021311673A patent/AU2021311673A1/en active Pending
- 2021-07-22 CA CA3189631A patent/CA3189631A1/en active Pending
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104940926A (zh) * | 2014-09-25 | 2015-09-30 | 信达生物制药(苏州)有限公司 | 重组融合蛋白制剂 |
CN105435222A (zh) * | 2014-09-25 | 2016-03-30 | 信达生物制药(苏州)有限公司 | 重组融合蛋白制剂 |
CN106620691A (zh) * | 2015-11-04 | 2017-05-10 | 信达生物制药(苏州)有限公司 | 一种重组全人源抗ctla-4单克隆抗体制剂及其应用 |
CN107686520A (zh) * | 2016-08-04 | 2018-02-13 | 信达生物制药(苏州)有限公司 | 抗pd‑l1纳米抗体及其应用 |
CN106913869A (zh) * | 2017-03-17 | 2017-07-04 | 信达生物制药(苏州)有限公司 | 一种抗ctla‑4单克隆抗体制剂及其应用 |
WO2019129137A1 (zh) | 2017-12-27 | 2019-07-04 | 信达生物制药(苏州)有限公司 | 抗lag-3抗体及其用途 |
CN109970856A (zh) * | 2017-12-27 | 2019-07-05 | 信达生物制药(苏州)有限公司 | 抗lag-3抗体及其用途 |
CN109970860A (zh) * | 2017-12-27 | 2019-07-05 | 信达生物制药(苏州)有限公司 | 三链抗体、其制备方法及其用途 |
CN109970857A (zh) * | 2017-12-27 | 2019-07-05 | 信达生物制药(苏州)有限公司 | 抗pd-l1抗体及其用途 |
CN110305210A (zh) * | 2018-03-27 | 2019-10-08 | 信达生物制药(苏州)有限公司 | 新型抗体分子、其制备方法及其用途 |
CN110678484A (zh) * | 2018-08-21 | 2020-01-10 | 天境生物 | 抗pd-l1/抗lag3双特异性抗体及其用途 |
Non-Patent Citations (8)
Title |
---|
"Peptide and Protein Drug Delivery", 1991, MARCEL DEKKER, INC, pages: 247 - 301 |
B. MINOWP. ROGGEK. THOMPSON, BIOPROCESS INTERNATIONAL, vol. 10, no. 6, 2012, pages 48 - 57 |
GENNARO: "Remington: the Science and Practice of Pharmacy", 2005, LIPPINCOTT WILLIAMS & WILKINS |
JONES, A., ADV. DRUG DELIVERY REV., vol. 10, 1993, pages 29 - 90 |
KELLEY ET AL.: "Weak partitioning chromatography for anion exchange purification of monoclonal antibodies", BIOTECHNOLOGY AND BIOENGINEERING, vol. 101, 2008, pages 553 - 566 |
NATIONAL PHARMACOPOEIA COMMITTEE: "Pharmacopoeia of the People 's Republic of China", 2015, article "Test for Visible Particles" |
ROWE ET AL.: "The Handbook of Pharmaceutical Excipients", 2003, AMERICAN PHARMACEUTICALS ASSOCIATION |
TUGCU: "Maximizing productivity of chromatography steps for purification of monoclonal antibodies", BIOTECHNOLOGY AND BIOENGINEERING, vol. 99, 2008, pages 599 - 613, XP002556043, DOI: 10.1002/bit.21604 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022268168A1 (zh) * | 2021-06-23 | 2022-12-29 | 迈威(上海)生物科技股份有限公司 | 靶向lag-3和pd-l1的新型双特异抗体及其应用 |
WO2023185732A1 (zh) * | 2022-03-28 | 2023-10-05 | 信达生物制药(新加坡)有限公司 | 包含抗Claudin18.2和CD3双特异性抗体的制剂及其制备方法和用途 |
Also Published As
Publication number | Publication date |
---|---|
AU2021311673A1 (en) | 2023-03-02 |
TW202206102A (zh) | 2022-02-16 |
CA3189631A1 (en) | 2022-01-27 |
JP2023535433A (ja) | 2023-08-17 |
EP4186522A1 (en) | 2023-05-31 |
US20230287124A1 (en) | 2023-09-14 |
TWI802942B (zh) | 2023-05-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2022017468A1 (zh) | Pd-l1/lag-3双特异性抗体制剂及其制备方法和用途 | |
TWI761869B (zh) | 包含抗cd47/pd-l1雙特異性抗體的製劑及其製備方法和用途 | |
JP2020518598A (ja) | 単独およびプログラム死受容体1(pd−1)抗体と組み合わされた抗ctla4抗体の安定な製剤、ならびにその使用方法 | |
TWI764097B (zh) | 包含抗cd47抗體的製劑及其製備方法和用途 | |
US20220002410A1 (en) | Co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
CN114146174B (zh) | 抗pd-l1/ox40双特异性抗体制剂及其制备方法和用途 | |
TWI782397B (zh) | 重組全人源抗tigit單株抗體製劑及其製備方法和用途 | |
CN111683681B (zh) | 包含抗ox40抗体的制剂、其制备方法及其用途 | |
WO2022111612A1 (zh) | 包含抗tigit/pd-1双特异性抗体的制剂及其制备方法和用途 | |
TWI802882B (zh) | 包含抗IL-23p19抗體的製劑、其製備方法和用途 | |
CN114007648B (zh) | 包含抗lag-3抗体的制剂、其制备方法及其用途 | |
CN116077646A (zh) | 一种抗冠状病毒s蛋白的抗体制剂及其制备方法和用途 | |
CN112675300A (zh) | 包含抗gitr抗体的制剂及其制备方法和用途 | |
TW202409078A (zh) | 穩定之包含抗gremlin1抗體的藥物製劑 | |
CN116077650A (zh) | 一种稳定的新冠中和抗体的药物组合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21845945 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3189631 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2023504418 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2021845945 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021845945 Country of ref document: EP Effective date: 20230223 |
|
ENP | Entry into the national phase |
Ref document number: 2021311673 Country of ref document: AU Date of ref document: 20210722 Kind code of ref document: A |